Home > Boards > US Listed > Biotechs > Halozyme Therapeutics (HALO)

If funds become readily available, Fred, I would

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
north40000 Member Profile
Member Level 
Followed By 172
Posts 15,079
Boards Moderated 0
Alias Born 01/19/06
160x600 placeholder
J&J's Janssen Seeks Europe OK For Subcutaneous Darzalex in Multiple Myeloma Dow Jones News - 7/19/2019 7:45:00 AM
Halozyme Announces Janssen Submits Extension Application To European Medicines Agency For Subcutaneous Formulation Of DARZALE... PR Newswire (US) - 7/19/2019 7:00:00 AM
Halozyme Announces First Clinical Dosing In argenx's Phase 1 Trial Of Efgartigimod (ARGX-113) With ENHANZE® Drug Delivery Te... PR Newswire (US) - 7/17/2019 8:00:00 AM
Halozyme Announces Janssen Submits BLA To FDA For Subcutaneous Formulation Of DARZALEX® Utilizing ENHANZE® Technology PR Newswire (US) - 7/12/2019 11:59:00 AM
Amended Statement of Beneficial Ownership (sc 13d/a) Edgar (US Regulatory) - 7/3/2019 4:02:19 PM
Halozyme Announces CRADA With National Institute of Allergy and Infectious Diseases For Use Of ENHANZE® Drug Delivery Techno... PR Newswire (US) - 6/25/2019 8:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/17/2019 8:20:11 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/12/2019 1:41:16 PM
Amended Statement of Beneficial Ownership (sc 13d/a) Edgar (US Regulatory) - 6/7/2019 5:11:39 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/4/2019 4:45:58 PM
Halozyme To Participate In Upcoming Investor Conferences PR Newswire (US) - 6/4/2019 8:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/3/2019 5:24:28 PM
Halozyme Announces argenx Has Selected Second Target Under ENHANZE® Technology Collaboration And License Agreement PR Newswire (US) - 5/22/2019 1:05:00 AM
Post-effective Amendment to an S-8 Filing (s-8 Pos) Edgar (US Regulatory) - 5/14/2019 5:11:52 PM
Post-effective Amendment to an S-8 Filing (s-8 Pos) Edgar (US Regulatory) - 5/14/2019 5:08:35 PM
Halozyme To Participate In Bank of America Merrill Lynch Health Care Conference 2019 PR Newswire (US) - 5/13/2019 8:01:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/7/2019 4:14:25 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/7/2019 4:07:11 PM
Halozyme Reports First Quarter 2019 Results PR Newswire (US) - 5/7/2019 4:01:00 PM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 5/6/2019 4:02:13 PM
Halozyme Names Dr. Alison A. Armour As Senior Vice President Of Research And Development PR Newswire (US) - 5/6/2019 8:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/3/2019 5:08:03 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/3/2019 4:30:05 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/3/2019 4:26:35 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/3/2019 4:23:56 PM
north40000 Member Level  Thursday, 02/14/19 03:58:15 PM
Re: Fred Kadiddlehopper post# 5591
Post # of 5652 
If funds become readily available, Fred, I would write Helen directly and suggest becoming a cardiovascular disease treatment company in addition to, or instead of, an oncology company. The links important to any company wishing to license from, partner with, or simply buy Amarin to be a wholly owned independent subsidiary are located in links under my avatar north40000 above, and “my stocks” accessed as above.

Helen should be impressed by the facts stated in those links, particularly the facts that

1) more people die from CVDs than from all cancers/tumors combined;

2) the treatment with Vascepa of such CVDs is highly effective nearly across the board, and at a very low cost(I pay $36 for an entire years supply of Vascepa). My own scrip for Vascepa was off- label for the already FDA-approved Vascepa for an indication I never had; my scrip resulted from family history of CVD + Type -1 diabetes that I had since 1957; my personal physician wrote that scrip, off label in 2013 and LabCorp analysis of vials of blood indicate to him that my risk for CVD has been “optimally suppressed” by the dosage of Vascepa I have taken every day since 4/01/2013;

3) the statements by Dr. Bhatt presented Nov. 10 in Chicago + the videos featuring Dr. Bhatt linked above;

4) the prescriptions for Vascepa last week were reported to be all time highs, and are expected to be further all time highs when reported early tomorrow morning(ESTime) on the IHub AMRN message board;

5) NEJM has published the results of Amarin’s Reduce-It clinical trial; first on-line the afternoon of November 10, and again in print version on January 3, 2019. Dr. Bhatt is lead author of that article.

6) Amarin has reported it will file its sNDA on or before the end of March 2019. The indications and label it will seek FDA approval for are unknown to me, but obviously will include the primary and pre-specified secondary indications specified in Reduce-It trial.

That’s it for now, Fred. As a SH, it is a suggestion. I expect there may be competition from other companies.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist